Table 3.
Clinical trials in GISTs with therapeutic targets in the PI3K/AKT/mTOR pathway.
| Drug | Trial Phase | Target | Condition | Status | Trial Number |
|---|---|---|---|---|---|
| BYL719+ Imatinib | Phase Ib | c-KIT + PI3K p110α | Third-line GISTs | Recruiting | NCT01735968 |
| BKM120+Imatinib | Phase Ib | c-KIT + PI3K Class I | Third-line GISTs | Recruiting | NCT01468488 |
| RAD001+ Imatinib | Phase II | c-KIT + mTOR | Progressive GISTs | ongoing | NCT00510354 |
| RAD001+ Imatinib | Phase I/II | c-KIT + mTOR | Resistant GISTs | Completed | NCT01275222 |
| Temsirolimus | Phase II | mTOR | GISTs | Completed | NCT00087074 |
| Perifosine+ Imatinib | Phase II | c-KIT + AKT | Resistant GISTs | Completed | NCT00455559 |
| Perifosine+ Sunitinib | Phase I/II | c-KIT + AKT | Advanced GISTs | Completed | NCT00399052 |